25 U.S. 'Highest Conviction' Stocks – UBS
A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 15 Analysts
Express News | HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $75 Price Target
Express News | Sarepta Therapeutics Inc - Anticipates Filing for Accelerated Approval of Srp-9003 in 2025
Express News | Sarepta Therapeutics Completes Enrollment in Emergene, a Phase 3 Clinical Study of Srp-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
